Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai MedicilonSHSE:688202 +3.44%63 EV-to-EBITDA is 414.67 as of Sep. 21, 2026, which is 890% above its 10-year median of 41.90. GuruFocus rates SHSE:688202 with a GF Score™ of 63/100 and a GF Value™ of ¥50.16 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 430 Biotechnology companies, Shanghai Medicilon ranks worse than 97.44% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Shanghai Medicilon's enterprise value is ¥14,500 Mil.
Shanghai Medicilon's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ¥35 Mil. Therefore, Shanghai Medicilon's EV-to-EBITDA for today is 414.67.
The historical rank and industry rank for Shanghai Medicilon's EV-to-EBITDA or its related term are showing as below:
SHSE:688202'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -172.37 Med: 41.9 Max: 418.16
Current: 414.66
During the past 10 years, the highest EV-to-EBITDA of Shanghai Medicilon was 418.16. The lowest was -172.37. And the median was 41.90.
SHSE:688202's EV-to-EBITDA is ranked worse than 97.44% of 430
companies
in the Biotechnology industry
Industry Median: 13.015
vs SHSE:688202: 414.66
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shanghai Medicilon's PE Ratio (TTM) for today is calculated as:
Shanghai Medicilon's share price for today is ¥109.85.
Shanghai Medicilon's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-0.783.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Shanghai Medicilon's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688202 vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Shanghai Medicilon's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Medicilon EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Medicilon's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Shanghai Medicilon's EV-to-EBITDA falls into.
Shanghai Medicilon's current Enterprise Value is ¥14,500 Mil.
Shanghai Medicilon's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥35 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Medicilon (SHSE:688202) has a EV-to-EBITDA of 414.67 as of Sep. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Shanghai Medicilon. This is 890% above median its historical median of 41.90. According to the industry distribution chart, Shanghai Medicilon ranks #419 out of 430 companies in the Biotechnology industry, placing it in the top 97.4%.
Is Shanghai Medicilon's EV-to-EBITDA too high?
Shanghai Medicilon's current EV-to-EBITDA of 414.67 is 890% above median its 10-year median of 41.90. The Biotechnology industry median EV-to-EBITDA is 13.02. Shanghai Medicilon's value of 414.67 is 3086.1% above this industry median. Based on the distribution chart, Shanghai Medicilon ranks #419 out of 430 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Shanghai Medicilon has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Medicilon's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Medicilon ranks #419 out of 430 companies for EV-to-EBITDA. This places Shanghai Medicilon in the lower half of its industry. The industry median EV-to-EBITDA is 13.02. Shanghai Medicilon's value of 414.67 is 3086.1% above this benchmark. While the company's 10-year median is 41.90 vs. the industry median of 13.02, Shanghai Medicilon has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.02, based on 430 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Medicilon's current EV-to-EBITDA of 414.67 is 3086.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Shanghai Medicilon. For the Biotechnology industry, the median EV-to-EBITDA is 13.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Medicilon's current EV-to-EBITDA is 414.67, which is 890% above median its own 10-year median of 41.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Medicilon stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Medicilon (SHSE:688202) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥50.16, compared to a current price of ¥109.85 — trading 119% above its estimated fair value. The current EV-to-EBITDA is 414.67, which is 890% above median its 10-year median of 41.90 and 3086.1% above the Biotechnology industry median of 13.02. Shanghai Medicilon's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Shanghai Medicilon (SHSE:688202), the current EV-to-EBITDA is 414.67 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Medicilon (SHSE:688202) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Medicilon stock appears to be overvalued.
The current stock price of ¥109.85 is trading 119% above its estimated GF Value™ of ¥50.16.
GuruFocus considers Shanghai Medicilon to be Significantly Overvalued.
Key valuation signals for SHSE:688202:
EV-to-EBITDA: 414.67 (890% above median its 10-year median of 41.90)
GF Value™: ¥50.16 vs. price of ¥109.85 (119% above fair value)
Industry Position: 3086.1% above the Biotechnology median (#419 of 430)
No single metric tells the full story. See the SHSE:688202 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Medicilon Inc is a comprehensive biomedical research and developemnt service company. It provides a full range of one-stop new drug development services for pharmaceutical companies and research institutions around the world in line with domestic and international reporting standards.
63GF Score
Get the complete analysis for SHSE:688202
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688202 has been successfully added to your 
